ALX Oncology (NASDAQ:ALXO) Earns “Buy” Rating from HC Wainwright

ALX Oncology (NASDAQ:ALXO)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 371.70% from the stock’s current price.

Other research analysts have also recently issued reports about the stock. Jefferies Financial Group raised shares of ALX Oncology from a “hold” rating to a “buy” rating and lifted their price target for the company from $2.00 to $3.00 in a research report on Thursday. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research note on Friday, January 24th. UBS Group decreased their price target on shares of ALX Oncology from $4.00 to $2.20 and set a “buy” rating for the company in a research report on Monday, January 27th. Finally, Piper Sandler raised their price objective on ALX Oncology from $8.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, ALX Oncology presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.14.

ALX Oncology Stock Performance

ALX Oncology stock opened at $1.06 on Friday. The company has a market cap of $55.91 million, a price-to-earnings ratio of -0.36 and a beta of 1.01. ALX Oncology has a 12 month low of $0.95 and a 12 month high of $17.83. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. The stock’s 50-day moving average is $1.39 and its 200-day moving average is $1.61.

Institutional Investors Weigh In On ALX Oncology

A number of large investors have recently added to or reduced their stakes in ALXO. JSF Financial LLC acquired a new stake in shares of ALX Oncology during the fourth quarter valued at about $29,000. GSA Capital Partners LLP purchased a new position in ALX Oncology in the third quarter valued at about $88,000. Barclays PLC boosted its holdings in ALX Oncology by 243.6% in the third quarter. Barclays PLC now owns 59,502 shares of the company’s stock valued at $107,000 after purchasing an additional 42,185 shares during the last quarter. Sei Investments Co. acquired a new stake in ALX Oncology during the 4th quarter valued at approximately $102,000. Finally, Bridgeway Capital Management LLC acquired a new stake in ALX Oncology during the 4th quarter valued at approximately $125,000. 97.97% of the stock is owned by institutional investors and hedge funds.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.